Share Price and Basic Stock Data
Last Updated: November 12, 2025, 2:16 pm
| PEG Ratio | 0.68 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Ajooni Biotech Ltd operates in the animal and shrimp feed industry, focusing on providing quality feed solutions. The company’s revenue has shown a notable upward trajectory, with sales reported at ₹74 Cr for the fiscal year ending March 2023, rising to ₹80 Cr for March 2024, and projected to reach ₹115 Cr for March 2025. This consistent growth reflects a robust demand for shrimp feed products, which is critical given the rising aquaculture industry in India. Quarterly sales figures also indicate volatility, with a peak of ₹41.26 Cr in March 2023, followed by a dip to ₹19.48 Cr in September 2023. However, sales rebounded to ₹25.66 Cr in June 2024, showcasing the company’s ability to adapt to market conditions. The overall trend of increasing sales underscores Ajooni’s strategic positioning within the sector, capitalizing on the growth of aquaculture and the rising consumption of shrimp products in both domestic and international markets.
Profitability and Efficiency Metrics
Ajooni Biotech’s profitability metrics indicate a mixed performance. The company’s operating profit margin (OPM) stood at 2.27%, significantly lower than the industry average, highlighting challenges in managing costs effectively. The operating profit for March 2024 was reported at ₹2 Cr, which fell to ₹1 Cr in March 2025, suggesting that while revenues are growing, operational efficiency needs enhancement. The return on equity (ROE) was recorded at 5.15%, while return on capital employed (ROCE) stood at 6.91%, both of which are relatively low compared to industry standards. The interest coverage ratio (ICR) exhibited a strong figure of 17.22x, indicating that Ajooni has a solid ability to cover its interest obligations, which is a positive sign for investors. However, the cash conversion cycle (CCC) of 129 days raises concerns about the efficiency of converting sales into cash, necessitating a review of inventory management and receivables collection processes.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ajooni Biotech reflects a conservative financial structure with total borrowings of ₹2 Cr against reserves of ₹54 Cr, indicating a low debt-to-equity ratio of 0.06. This signifies a strong equity base that provides financial stability, especially crucial in the highly competitive feed industry. The current ratio stood at a healthy 12.86, suggesting ample liquidity to meet short-term obligations. However, the company’s price-to-book value (P/BV) ratio of 1.10x indicates that the stock is trading at a slight premium to its book value, which may reflect market optimism. The asset turnover ratio of 1.61% suggests moderate efficiency in utilizing assets to generate revenue, while the net profit margin of 2.94% indicates room for improvement in profitability. Overall, Ajooni’s balance sheet appears robust, but enhancing operational efficiency could yield better returns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ajooni Biotech Ltd reveals a diverse ownership structure, with promoters holding 26.89% as of June 2025, a slight decline from previous quarters, indicating reduced insider confidence or potential liquidity events. The public holds a substantial 73.11% stake, reflecting strong retail investor interest. Foreign Institutional Investors (FIIs) have minimal presence, with 0.00% reported in recent quarters, which may suggest hesitance from institutional investors towards the stock. The number of shareholders has consistently increased, from 8,142 in September 2022 to 63,305 by June 2025, indicating growing interest and trust among retail investors. This expanding base of shareholders can be a positive indicator of market confidence, although the lack of institutional backing may pose risks regarding stock volatility and price stability.
Outlook, Risks, and Final Insight
Looking ahead, Ajooni Biotech is well-positioned to capitalize on the growing demand for shrimp feed, supported by its reported sales growth. However, challenges remain, particularly in improving profitability and operational efficiency, as indicated by low margins and high cash conversion cycles. The reliance on public investors without significant institutional support may expose the company to price volatility. Additionally, the fluctuating sales figures suggest that while the market is expanding, Ajooni must navigate competitive pressures effectively. Strengths include a solid equity base and low debt levels, while risks involve operational inefficiencies and market competition. Ajooni’s future performance will depend on its ability to enhance profitability, maintain liquidity, and expand its market share while managing these inherent risks.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ajooni Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Narmada Agrobase Ltd | 83.0 Cr. | 21.9 | 28.4/14.6 | 20.3 | 14.7 | 0.00 % | 13.0 % | 11.2 % | 10.0 |
| Godrej Agrovet Ltd | 11,020 Cr. | 573 | 876/564 | 25.3 | 94.1 | 1.89 % | 16.6 % | 17.7 % | 10.0 |
| Avanti Feeds Ltd | 10,027 Cr. | 736 | 965/563 | 16.2 | 221 | 1.21 % | 24.0 % | 19.5 % | 1.00 |
| Ajooni Biotech Ltd | 85.8 Cr. | 4.98 | 8.55/4.80 | 23.4 | 5.11 | 0.00 % | 6.91 % | 5.15 % | 2.00 |
| Industry Average | 10,523.50 Cr | 333.97 | 21.30 | 83.73 | 0.78% | 15.13% | 13.39% | 5.75 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.31 | 10.29 | 10.63 | 41.26 | 21.00 | 19.48 | 20.05 | 19.58 | 25.66 | 25.72 | 34.03 | 29.27 | 31.27 |
| Expenses | 11.55 | 9.70 | 10.15 | 40.32 | 20.34 | 18.85 | 20.70 | 17.99 | 24.70 | 24.95 | 33.10 | 28.26 | 30.56 |
| Operating Profit | 0.76 | 0.59 | 0.48 | 0.94 | 0.66 | 0.63 | -0.65 | 1.59 | 0.96 | 0.77 | 0.93 | 1.01 | 0.71 |
| OPM % | 6.17% | 5.73% | 4.52% | 2.28% | 3.14% | 3.23% | -3.24% | 8.12% | 3.74% | 2.99% | 2.73% | 3.45% | 2.27% |
| Other Income | 0.01 | 0.00 | 0.02 | 0.26 | 0.07 | 0.29 | 1.57 | 0.26 | 0.04 | 0.31 | 0.39 | 1.34 | 0.65 |
| Interest | 0.10 | 0.13 | 0.13 | 0.12 | 0.13 | 0.19 | 0.12 | 0.11 | 0.15 | 0.06 | 0.07 | 0.06 | 0.08 |
| Depreciation | 0.25 | 0.25 | 0.26 | 0.24 | 0.21 | 0.21 | 0.21 | 0.24 | 0.22 | 0.23 | 0.24 | 0.38 | 0.25 |
| Profit before tax | 0.42 | 0.21 | 0.11 | 0.84 | 0.39 | 0.52 | 0.59 | 1.50 | 0.63 | 0.79 | 1.01 | 1.91 | 1.03 |
| Tax % | 23.81% | 19.05% | 0.00% | 35.71% | -2.56% | 23.08% | 23.73% | 38.67% | 25.40% | 22.78% | 27.72% | 19.37% | 24.27% |
| Net Profit | 0.32 | 0.16 | 0.11 | 0.54 | 0.40 | 0.40 | 0.44 | 0.91 | 0.47 | 0.62 | 0.73 | 1.54 | 0.78 |
| EPS in Rs | 0.02 | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.03 | 0.05 | 0.03 | 0.04 | 0.04 | 0.09 | 0.05 |
Last Updated: August 20, 2025, 2:35 pm
Below is a detailed analysis of the quarterly data for Ajooni Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 31.27 Cr.. The value appears strong and on an upward trend. It has increased from 29.27 Cr. (Mar 2025) to 31.27 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Jun 2025, the value is 30.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.26 Cr. (Mar 2025) to 30.56 Cr., marking an increase of 2.30 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.71 Cr.. The value appears to be declining and may need further review. It has decreased from 1.01 Cr. (Mar 2025) to 0.71 Cr., marking a decrease of 0.30 Cr..
- For OPM %, as of Jun 2025, the value is 2.27%. The value appears to be declining and may need further review. It has decreased from 3.45% (Mar 2025) to 2.27%, marking a decrease of 1.18%.
- For Other Income, as of Jun 2025, the value is 0.65 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Mar 2025) to 0.65 Cr., marking a decrease of 0.69 Cr..
- For Interest, as of Jun 2025, the value is 0.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.25 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.38 Cr. (Mar 2025) to 0.25 Cr., marking a decrease of 0.13 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.03 Cr.. The value appears to be declining and may need further review. It has decreased from 1.91 Cr. (Mar 2025) to 1.03 Cr., marking a decrease of 0.88 Cr..
- For Tax %, as of Jun 2025, the value is 24.27%. The value appears to be increasing, which may not be favorable. It has increased from 19.37% (Mar 2025) to 24.27%, marking an increase of 4.90%.
- For Net Profit, as of Jun 2025, the value is 0.78 Cr.. The value appears to be declining and may need further review. It has decreased from 1.54 Cr. (Mar 2025) to 0.78 Cr., marking a decrease of 0.76 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.05. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to 0.05, marking a decrease of 0.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 4:16 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 7 | 13 | 29 | 42 | 40 | 40 | 51 | 74 | 74 | 80 | 115 | 120 |
| Expenses | 1 | 7 | 13 | 28 | 41 | 39 | 39 | 49 | 71 | 72 | 78 | 111 | 117 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 4 | 3 |
| OPM % | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 3% | 4% | 4% | 3% | 3% | 3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 5 |
| Tax % | 0% | 27% | 29% | 28% | 20% | 15% | 29% | 26% | 28% | 28% | 28% | 22% | |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 |
| EPS in Rs | 0.02 | 0.12 | 0.18 | 0.36 | 0.03 | 0.03 | 0.02 | 0.02 | 0.05 | 0.06 | 0.12 | 0.20 | 0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% |
Ajooni Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 47% |
| 5 Years: | 56% |
| 3 Years: | 47% |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -19% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 4, 2025, 9:40 pm
Balance Sheet
Last Updated: June 16, 2025, 12:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.24 | 0.24 | 0.24 | 0.33 | 6 | 6 | 8 | 10 | 10 | 18 | 18 | 34 |
| Reserves | 0 | 0 | 0 | 1 | 5 | 6 | 7 | 6 | 6 | 24 | 25 | 54 |
| Borrowings | 0 | 0 | 1 | 1 | 5 | 5 | 5 | 7 | 5 | 5 | 2 | 2 |
| Other Liabilities | 0 | 1 | 1 | 11 | 4 | 1 | 2 | 6 | 7 | 12 | 3 | 5 |
| Total Liabilities | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 |
| Fixed Assets | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 | 6 | 6 | 10 | 11 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Investments | 0 | 0 | 0 | 6 | 6 | 4 | 3 | 1 | 1 | 4 | 2 | 3 |
| Other Assets | 0 | 1 | 2 | 6 | 12 | 13 | 18 | 22 | 22 | 48 | 34 | 80 |
| Total Assets | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 |
Below is a detailed analysis of the balance sheet data for Ajooni Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 16.00 Cr..
- For Reserves, as of Mar 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 29.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2024) to 5.00 Cr., marking an increase of 2.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 95.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 48.00 Cr. (Mar 2024) to 95.00 Cr., marking an increase of 47.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 80.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Mar 2024) to 80.00 Cr., marking an increase of 46.00 Cr..
- For Total Assets, as of Mar 2025, the value is 95.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2024) to 95.00 Cr., marking an increase of 47.00 Cr..
Notably, the Reserves (54.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | -1.00 | 0.00 | -4.00 | -4.00 | -4.00 | -5.00 | -2.00 | -2.00 | 0.00 | 2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 40 | 33 | 17 | 25 | 44 | 115 | 98 | 68 | 101 | 59 | 52 |
| Inventory Days | 141 | 22 | 14 | 63 | 19 | 51 | 34 | 46 | 34 | 39 | 80 | 90 |
| Days Payable | 100 | 66 | 27 | 79 | 9 | 12 | 20 | 46 | 39 | 56 | 8 | 13 |
| Cash Conversion Cycle | 99 | -4 | 20 | 1 | 35 | 84 | 129 | 98 | 63 | 83 | 131 | 129 |
| Working Capital Days | 96 | 5 | 9 | -29 | -1 | 84 | 105 | 77 | 58 | 94 | 132 | 160 |
| ROCE % | 28% | 18% | 37% | 10% | 4% | 4% | 5% | 9% | 6% | 8% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Diluted EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Cash EPS (Rs.) | 0.25 | 0.34 | 0.24 | 2.16 | 0.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Revenue From Operations / Share (Rs.) | 6.66 | 9.14 | 8.50 | 74.00 | 51.01 |
| PBDIT / Share (Rs.) | 0.33 | 0.50 | 0.34 | 3.11 | 1.66 |
| PBIT / Share (Rs.) | 0.27 | 0.40 | 0.23 | 2.00 | 1.09 |
| PBT / Share (Rs.) | 0.25 | 0.34 | 0.17 | 1.46 | 0.50 |
| Net Profit / Share (Rs.) | 0.19 | 0.24 | 0.12 | 1.05 | 0.37 |
| PBDIT Margin (%) | 5.01 | 5.52 | 4.10 | 4.20 | 3.26 |
| PBIT Margin (%) | 4.06 | 4.43 | 2.75 | 2.70 | 2.13 |
| PBT Margin (%) | 3.77 | 3.73 | 2.11 | 1.97 | 0.98 |
| Net Profit Margin (%) | 2.94 | 2.69 | 1.50 | 1.41 | 0.73 |
| Return on Networth / Equity (%) | 3.82 | 5.06 | 2.69 | 6.40 | 2.38 |
| Return on Capital Employeed (%) | 5.16 | 7.98 | 4.72 | 10.55 | 6.20 |
| Return On Assets (%) | 3.54 | 4.54 | 1.91 | 3.61 | 1.33 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.04 | 0.15 | 0.12 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.12 | 0.32 | 0.43 |
| Asset Turnover Ratio (%) | 1.61 | 1.51 | 1.70 | 2.60 | 2.00 |
| Current Ratio (X) | 12.86 | 10.74 | 2.28 | 2.18 | 2.05 |
| Quick Ratio (X) | 7.89 | 5.63 | 1.82 | 1.60 | 1.53 |
| Inventory Turnover Ratio (X) | 5.83 | 6.25 | 10.27 | 11.35 | 10.01 |
| Interest Coverage Ratio (X) | 17.22 | 7.95 | 6.40 | 5.76 | 2.85 |
| Interest Coverage Ratio (Post Tax) (X) | 11.09 | 4.88 | 3.35 | 2.94 | 1.64 |
| Enterprise Value (Cr.) | 95.06 | 53.43 | 39.48 | 72.63 | 36.96 |
| EV / Net Operating Revenue (X) | 0.82 | 0.66 | 0.52 | 0.98 | 0.72 |
| EV / EBITDA (X) | 16.51 | 12.07 | 12.90 | 23.34 | 22.19 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| Price / BV (X) | 1.10 | 1.21 | 0.83 | 4.11 | 1.94 |
| Price / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| EarningsYield | 0.03 | 0.04 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ajooni Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.66. It has decreased from 9.14 (Mar 24) to 6.66, marking a decrease of 2.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.50 (Mar 24) to 0.33, marking a decrease of 0.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.27, marking a decrease of 0.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.25. This value is within the healthy range. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 2. It has decreased from 0.24 (Mar 24) to 0.19, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 5.01. This value is below the healthy minimum of 10. It has decreased from 5.52 (Mar 24) to 5.01, marking a decrease of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 10. It has decreased from 4.43 (Mar 24) to 4.06, marking a decrease of 0.37.
- For PBT Margin (%), as of Mar 25, the value is 3.77. This value is below the healthy minimum of 10. It has increased from 3.73 (Mar 24) to 3.77, marking an increase of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 2.69 (Mar 24) to 2.94, marking an increase of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 15. It has decreased from 5.06 (Mar 24) to 3.82, marking a decrease of 1.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.16. This value is below the healthy minimum of 10. It has decreased from 7.98 (Mar 24) to 5.16, marking a decrease of 2.82.
- For Return On Assets (%), as of Mar 25, the value is 3.54. This value is below the healthy minimum of 5. It has decreased from 4.54 (Mar 24) to 3.54, marking a decrease of 1.00.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.61. It has increased from 1.51 (Mar 24) to 1.61, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 12.86. This value exceeds the healthy maximum of 3. It has increased from 10.74 (Mar 24) to 12.86, marking an increase of 2.12.
- For Quick Ratio (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 2. It has increased from 5.63 (Mar 24) to 7.89, marking an increase of 2.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has decreased from 6.25 (Mar 24) to 5.83, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.22. This value is within the healthy range. It has increased from 7.95 (Mar 24) to 17.22, marking an increase of 9.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 11.09, marking an increase of 6.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 95.06. It has increased from 53.43 (Mar 24) to 95.06, marking an increase of 41.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.82, marking an increase of 0.16.
- For EV / EBITDA (X), as of Mar 25, the value is 16.51. This value exceeds the healthy maximum of 15. It has increased from 12.07 (Mar 24) to 16.51, marking an increase of 4.44.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For Price / BV (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has decreased from 1.21 (Mar 24) to 1.10, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajooni Biotech Ltd:
- Net Profit Margin: 2.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.16% (Industry Average ROCE: 15.13%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.82% (Industry Average ROE: 13.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.09
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.4 (Industry average Stock P/E: 21.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Animal/Shrimp Feed | D-118, Industrial Area, Phase - VII, Mohali Punjab 160055 | info@ajoonibiotech.com http://www.ajoonibiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jasjot Singh | Managing Director & CFO |
| Mr. Gursimran Singh | Whole Time Director |
| Mr. Partek Singh | Director |
| Mr. Ramandeep Singh | Independent Director |
| Mr. Imteshwar Singh | Independent Director |
| Ms. Simmi Chabbra | Independent Director |
| Mr. Ishtneet Bhatia | Independent Director |
FAQ
What is the intrinsic value of Ajooni Biotech Ltd?
Ajooni Biotech Ltd's intrinsic value (as of 12 November 2025) is 5.02 which is 0.80% higher the current market price of 4.98, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 85.8 Cr. market cap, FY2025-2026 high/low of 8.55/4.80, reserves of ₹54 Cr, and liabilities of 95 Cr.
What is the Market Cap of Ajooni Biotech Ltd?
The Market Cap of Ajooni Biotech Ltd is 85.8 Cr..
What is the current Stock Price of Ajooni Biotech Ltd as on 12 November 2025?
The current stock price of Ajooni Biotech Ltd as on 12 November 2025 is 4.98.
What is the High / Low of Ajooni Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajooni Biotech Ltd stocks is 8.55/4.80.
What is the Stock P/E of Ajooni Biotech Ltd?
The Stock P/E of Ajooni Biotech Ltd is 23.4.
What is the Book Value of Ajooni Biotech Ltd?
The Book Value of Ajooni Biotech Ltd is 5.11.
What is the Dividend Yield of Ajooni Biotech Ltd?
The Dividend Yield of Ajooni Biotech Ltd is 0.00 %.
What is the ROCE of Ajooni Biotech Ltd?
The ROCE of Ajooni Biotech Ltd is 6.91 %.
What is the ROE of Ajooni Biotech Ltd?
The ROE of Ajooni Biotech Ltd is 5.15 %.
What is the Face Value of Ajooni Biotech Ltd?
The Face Value of Ajooni Biotech Ltd is 2.00.